Cargando…

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy

Triple negative breast cancer (TNBC) is marked by a lack of expression of the Estrogen Receptor, Progesterone Receptor, and human epidermal growth factor receptor 2. Therefore, targeted therapies are being investigated based on the expression profiles of tumors. Due to the potential for acquired and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefanski, Casey D., Prosperi, Jenifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992589/ https://www.ncbi.nlm.nih.gov/pubmed/35582533 http://dx.doi.org/10.20517/cdr.2021.128

Ejemplares similares

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
por: McHenry, Peter R., et al.
Publicado: (2023)

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
por: Bryant, Christopher, et al.
Publicado: (2014)

APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells
por: Stefanski, Casey D., et al.
Publicado: (2019)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
por: Stefanski, Casey D., et al.
Publicado: (2020)

The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy
por: Zhou, Zhi-rui, et al.
Publicado: (2017)

Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer
por: Lim, Sera, et al.
Publicado: (2020)

β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
por: Xu, Jinhua, et al.
Publicado: (2015)

APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation
por: VanKlompenberg, Monica K., et al.
Publicado: (2017)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Bioactive nanotherapeutic trends to combat triple negative breast cancer
por: Chowdhury, Pallabita, et al.
Publicado: (2021)

Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR
por: Wang, Yuan-Liang, et al.
Publicado: (2015)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

RNA nanoparticles for targeted therapies of triple-negative breast cancers
por: Danai, Leyla, et al.
Publicado: (2023)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2022)

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
por: Varley, Jenny, et al.
Publicado: (2003)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
por: Raman, Dayanidhi, et al.
Publicado: (2020)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
por: MacDonald, Isaiah, et al.
Publicado: (2022)

Super-enhanced MARCO variant drives triple-negative breast cancer progression
por: Lin, Weei-Chin, et al.
Publicado: (2022)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation
por: Choi, Changhoon, et al.
Publicado: (2020)

Mucoadhesive nanoformulations and their potential for combating COVID-19
por: Prasher, Parteek, et al.
Publicado: (2021)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer
por: Stefanski, Casey D., et al.
Publicado: (2023)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer
por: Kim, Donghwa, et al.
Publicado: (2021)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
por: Nowsheen, Somaira, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cftcus37f8aor3oa6l7h1g6l41